| Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study. | |
| | |
MedLine Citation:
|
PMID: 21946898 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVES: CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. METHODS: In a total of 80 incident simvastatin users, the association between the CYP3A4 intron 6 C>T SNP (rs35599367) and reduction in cholesterol levels was analyzed using linear regression analysis and adjusting for potential confounding factors. RESULTS: The CYP3A4*22 allele was associated with a trend towards a stronger simvastatin lipid-lowering response, as reflected by the greater reduction in both TOTc and LDLc levels when compared with homozygous wild type. We observed that the CYP3A4*22 allele carriers had an increased reduction in TOTc and LDLc: -0.25 mmol/l (95% confidence interval [CI95%]=[-0.52; 0.01], P=0.058) and -0.29 mmol/l (CI95%=[-0.58; 0.01], P=0.054) when compared with homozygous CC. When we adjusted the model for potential confounding factors, the corresponding reduction in TOTc was -0.31 mmol/l (CI95%=[-0.59;-0.04], P=0.028) and for LDLc -0.34 mmol/l (CI95%=[-0.66; -0.02], P=0.034) greater for CYP3A4*22 allele carriers when compared with homozygotes wild type. CONCLUSION: The CYP3A4*22 intron 6 SNP T-variant allele was associated with reduced CYP3A4 activity, resulting in a better lipid lowering response to simvastatin, when data were adjusted for confounding factors. This observation is a step towards the clarification of the reasons of interindividual variability in statins response and may potentially lead to improved tailoring of simvastatin therapy. |
| | |
Authors:
|
Laure Elens; Matthijs L Becker; Vincent Haufroid; Albert Hofman; Loes E Visser; André G Uitterlinden; Bruno Ch Stricker; Ron H N van Schaik |
Related Documents
:
|
18302158 - Frequent biallelic inactivation and transcriptional silencing of the diras3 gene at 1p3... 18928468 - Paediatric bilateral adrenal phaeochromocytomas in association with a novel mutation in... 23550138 - The biotinidase gene variants registry: a paradigm public database. 8625318 - P27/kip1 mutation found in breast cancer. 8533208 - Detection of aberrations in androgen receptor gene by analysis of single-stranded confo... 9778168 - The kin-cohort study for estimating penetrance. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-22 |
Journal Detail:
|
Title: Pharmacogenetics and genomics Volume: - ISSN: 1744-6880 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101231005 Medline TA: Pharmacogenet Genomics Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
aDepartments of Clinical Chemistry bHospital Pharmacy cEpidemiology dInternal Medicine eMedical Informatics, Erasmus Medical Center fSTAR Medical Diagnostic Center, Rotterdam, The Netherlands gUniversité catholique de Louvain, Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Bruxelles, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a pane...
Next Document: Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with ...